Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2017

01-02-2017 | Epidemiology

Recurrence risk perception and quality of life following treatment of breast cancer

Authors: Sarah T. Hawley, Nancy K. Janz, Kent A. Griffith, Reshma Jagsi, Christopher R. Friese, Allison W. Kurian, Ann S. Hamilton, Kevin C. Ward, Monica Morrow, Lauren P. Wallner, Steven J. Katz

Published in: Breast Cancer Research and Treatment | Issue 3/2017

Login to get access

Abstract

Purpose

Little is known about different ways of assessing risk of distant recurrence following cancer treatment (e.g., numeric or descriptive). We sought to evaluate the association between overestimation of risk of distant recurrence of breast cancer and key patient-reported outcomes, including quality of life and worry.

Methods

We surveyed a weighted random sample of newly diagnosed patients with early-stage breast cancer identified through SEER registries of Los Angeles County & Georgia (2013–14) ~2 months after surgery (N = 2578, RR = 71%). Actual 10-year risk of distant recurrence after treatment was based on clinical factors for women with DCIS & low-risk invasive cancer (Stg 1A, ER+, HER2−, Gr 1–2). Women reported perceptions of their risk numerically (0–100%), with values ≥10% for DCIS & ≥20% for invasive considered overestimates. Perceptions of “moderate, high or very high” risk were considered descriptive overestimates. In our analytic sample (N = 927), we assessed factors correlated with both types of overestimation and report multivariable associations between overestimation and QoL (PROMIS physical & mental health) and frequent worry.

Results

30.4% of women substantially overestimated their risk of distant recurrence numerically and 14.7% descriptively. Few factors other than family history were significantly associated with either type of overestimation. Both types of overestimation were significantly associated with frequent worry, and lower QoL.

Conclusions

Ensuring understanding of systemic recurrence risk, particularly among patients with favorable prognosis, is important. Better risk communication by clinicians may translate to better risk comprehension among patients and to improvements in QoL.
Literature
2.
go back to reference Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005–2014. doi:10.1056/NEJMoa1510764 CrossRefPubMedPubMedCentral Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005–2014. doi:10.​1056/​NEJMoa1510764 CrossRefPubMedPubMedCentral
3.
go back to reference Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU (2014) Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 32(20):2142–2150. doi:10.1200/jco.2013.53.1608 CrossRefPubMedPubMedCentral Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU (2014) Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 32(20):2142–2150. doi:10.​1200/​jco.​2013.​53.​1608 CrossRefPubMedPubMedCentral
6.
go back to reference Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E (2008) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100(4):243–251. doi:10.1093/jnci/djn010 CrossRefPubMed Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E (2008) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100(4):243–251. doi:10.​1093/​jnci/​djn010 CrossRefPubMed
7.
go back to reference Haas JS, Kaplan CP, Des Jarlais G, Gildengoin V, Perez-Stable EJ, Kerlikowske K (2005) Perceived risk of breast cancer among women at average and increased risk. J Women’s Health 14(9):845–851. doi:10.1089/jwh.2005.14.845 CrossRef Haas JS, Kaplan CP, Des Jarlais G, Gildengoin V, Perez-Stable EJ, Kerlikowske K (2005) Perceived risk of breast cancer among women at average and increased risk. J Women’s Health 14(9):845–851. doi:10.​1089/​jwh.​2005.​14.​845 CrossRef
8.
go back to reference Liu Y, Perez M, Aft RL, Massman K, Robinson E, Myles S, Schootman M, Gillanders WE, Jeffe DB (2010) Accuracy of perceived risk of recurrence among patients with early-stage breast cancer. Cancer Epidemiol Biomark Prevent 19(3):675–680. doi:10.1158/1055-9965.epi-09-1051 CrossRef Liu Y, Perez M, Aft RL, Massman K, Robinson E, Myles S, Schootman M, Gillanders WE, Jeffe DB (2010) Accuracy of perceived risk of recurrence among patients with early-stage breast cancer. Cancer Epidemiol Biomark Prevent 19(3):675–680. doi:10.​1158/​1055-9965.​epi-09-1051 CrossRef
9.
go back to reference Fisher CS, Martin-Dunlap T, Ruppel MB, Gao F, Atkins J, Margenthaler JA (2012) Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann Surg Oncol 19(10):3246–3250. doi:10.1245/s10434-012-2525-x CrossRefPubMed Fisher CS, Martin-Dunlap T, Ruppel MB, Gao F, Atkins J, Margenthaler JA (2012) Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann Surg Oncol 19(10):3246–3250. doi:10.​1245/​s10434-012-2525-x CrossRefPubMed
10.
12.
go back to reference Hamilton AS, Hofer TP, Hawley ST, Morrell D, Leventhal M, Deapen D, Salem B, Katz SJ (2009) Latinas and breast cancer outcomes: population-based sampling, ethnic identity, and acculturation assessment. Cancer Epidemiol Biomark Prevent 18(7):2022–2029. doi:10.1158/1055-9965.epi-09-0238 CrossRef Hamilton AS, Hofer TP, Hawley ST, Morrell D, Leventhal M, Deapen D, Salem B, Katz SJ (2009) Latinas and breast cancer outcomes: population-based sampling, ethnic identity, and acculturation assessment. Cancer Epidemiol Biomark Prevent 18(7):2022–2029. doi:10.​1158/​1055-9965.​epi-09-0238 CrossRef
13.
go back to reference Dillman D, Smyth J, Christian L (2009) Internet, mail, and mixed-mode surveys: the tailored design method, 3rd edn. Wiley, Hoboken Dillman D, Smyth J, Christian L (2009) Internet, mail, and mixed-mode surveys: the tailored design method, 3rd edn. Wiley, Hoboken
15.
go back to reference Janz NK, Hawley ST, Mujahid MS, Griggs JJ, Alderman A, Hamilton AS, Graff JJ, Jagsi R, Katz SJ (2011) Correlates of worry about recurrence in a multiethnic population-based sample of women with breast cancer. Cancer 117(9):1827–1836. doi:10.1002/cncr.25740 CrossRefPubMedPubMedCentral Janz NK, Hawley ST, Mujahid MS, Griggs JJ, Alderman A, Hamilton AS, Graff JJ, Jagsi R, Katz SJ (2011) Correlates of worry about recurrence in a multiethnic population-based sample of women with breast cancer. Cancer 117(9):1827–1836. doi:10.​1002/​cncr.​25740 CrossRefPubMedPubMedCentral
16.
go back to reference Hawley ST, Griggs JJ, Hamilton AS, Graff JJ, Janz NK, Morrow M, Jagsi R, Salem B, Katz SJ (2009) Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients. J Natl Cancer Inst 101(19):1337–1347CrossRefPubMedPubMedCentral Hawley ST, Griggs JJ, Hamilton AS, Graff JJ, Janz NK, Morrow M, Jagsi R, Salem B, Katz SJ (2009) Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients. J Natl Cancer Inst 101(19):1337–1347CrossRefPubMedPubMedCentral
17.
go back to reference PROMIS Patient-Reported Outcomes Measurement Information System: dynamic tools to measure health outcomes from the patient perspective. http://www.nihpromis.org. Accessed 24 June 2016 PROMIS Patient-Reported Outcomes Measurement Information System: dynamic tools to measure health outcomes from the patient perspective. http://​www.​nihpromis.​org. Accessed 24 June 2016
18.
go back to reference Weaver KE, Forsythe LP, Reeve BB, Alfano CM, Rodriguez JL, Sabatino SA, Hawkins NA, Rowland JH (2012) Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomark Prev 21(11):2108–2117. doi:10.1158/1055-9965.epi-12-0740 CrossRef Weaver KE, Forsythe LP, Reeve BB, Alfano CM, Rodriguez JL, Sabatino SA, Hawkins NA, Rowland JH (2012) Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomark Prev 21(11):2108–2117. doi:10.​1158/​1055-9965.​epi-12-0740 CrossRef
19.
go back to reference Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P (2001) A multivariate technique for multiply imputing missing values using a sequence of regression models. Survey Methodol 27(1):85–96 Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P (2001) A multivariate technique for multiply imputing missing values using a sequence of regression models. Survey Methodol 27(1):85–96
21.
22.
go back to reference Zikmund-Fisher BJ, Janz NK, Hawley ST, Griffith KA, Sabolch A, Jagsi R (2016) Communication of recurrence risk estimates to patients diagnosed with breast cancer. JAMA Oncol. doi:10.1001/jamaoncol.2015.6416 Zikmund-Fisher BJ, Janz NK, Hawley ST, Griffith KA, Sabolch A, Jagsi R (2016) Communication of recurrence risk estimates to patients diagnosed with breast cancer. JAMA Oncol. doi:10.​1001/​jamaoncol.​2015.​6416
23.
go back to reference Janz NK, Leinberger RL, Zikmund-Fisher BJ, Hawley ST, Griffith K, Jagsi R (2015) Provider perspectives on presenting risk information and managing worry about recurrence among breast cancer survivors. Psycho-oncology 24(5):592–600. doi:10.1002/pon.3625 CrossRefPubMed Janz NK, Leinberger RL, Zikmund-Fisher BJ, Hawley ST, Griffith K, Jagsi R (2015) Provider perspectives on presenting risk information and managing worry about recurrence among breast cancer survivors. Psycho-oncology 24(5):592–600. doi:10.​1002/​pon.​3625 CrossRefPubMed
24.
go back to reference The Joint Commission (2007) What did the doctor say?: Improving health literacy to protect patient safety. The Joint Commission, Oakbrook Terrace The Joint Commission (2007) What did the doctor say?: Improving health literacy to protect patient safety. The Joint Commission, Oakbrook Terrace
25.
Metadata
Title
Recurrence risk perception and quality of life following treatment of breast cancer
Authors
Sarah T. Hawley
Nancy K. Janz
Kent A. Griffith
Reshma Jagsi
Christopher R. Friese
Allison W. Kurian
Ann S. Hamilton
Kevin C. Ward
Monica Morrow
Lauren P. Wallner
Steven J. Katz
Publication date
01-02-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-4082-7

Other articles of this Issue 3/2017

Breast Cancer Research and Treatment 3/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine